Abbott forms US pact to develop rapid acute renal failure urine test
This article was originally published in Clinica
Executive Summary
Abbott has signed an exclusive agreement with Cincinnati Children's Hospital (CCH) to develop a urine test for acute renal failure (ARF) based on a marker that has recently emerged as a tool that could "transform the clinical approach to kidney disease". The biomarker, known as NGAL (neutrophil gelatinase-associated lipocalcin), was last year also exclusively licensed to Biosite to make serum and plasma-based tests (see Clinica No 1167, p 18).
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.